Data were presented at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium in San Francisco

Those data were presented at the American Society of Clinical Oncology's 2013 Gastrointestinal Cancers Symposium in San Francisco

Tasimelteon-treated patients maintained their clinical benefits while placebo-treated patients showed significant deterioration in measures of nighttime sleep, daytime naps and timing of sleep...VistaGen Therapeutics Inc., of South San Francisco, said it completed its final Phase I study of AV-101, an oral prodrug candidate in development for multiple conditions involving chronic neuropathic pain

Clinical Cancer Research included a paper that suggested the compound, ENMD-2076, acts potently against breast cancer cell lines that lack expression of the estrogen and progesterone receptors, while also lacking HER2 amplification, i.e., TNBC...KaloBios Pharmaceuticals Inc., of South San Francisco, set the terms on its previously disclosed initial public offering

Secondary endpoints also were met, including the clinical cure rate at end of treatment day 10 to day 14 (88.9 percent) and test of cure at day 21 to day 28 (100 percent...That allows Lorus to initiate a biomarker clinical investigation to further explore the effects of the drug at relevant doses determined in the trial...The complete clinical study report for the interim analysis would be supplied to the FDA during the review within 60 days of the resubmission

Celtaxys Inc., of San Francisco, said it started a Phase I study of CTX-4430, which is designed to block pro-inflammatory enzyme leukotriene A4 hydrolase...Durata said the secondary endpoint of clinical success at the end of treatment – the expected primary endpoint for regulatory review in Europe – also was met

Alnylam Pharmaceuticals Inc., of Cambridge, Mass., filed a clinical trial application with the U.K. Medicines and Healthcare Products Regulatory Agency to initiate a Phase I study of ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR), in TTR-mediated amyloidosis...Onyx Pharmaceuticals Inc., of South San Francisco, and Bayer AG, of Leverkusen, Germany, reported that a Phase III trial of Nexavar (sorafenib) in locally advanced or metastatic radioactive iodine-refractory differentiated

BCI-838 showed a favorable safety profile, with no treatment-related trends in clinical laboratory results, vital sign measurements, 12 lead ECG results or physical examination findings, and the drug was well tolerated up to the dose levels predicted for efficacy...Theravance Inc., of South San Francisco, said it started a Phase II study testing TD-9855, its lead monoamine reuptake inhibitor program, in patients with fibromyalgia

Talon Therapeutics Inc., of South San Francisco, said complete data from its Phase II RALLY study of Marqibo, a spingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate, were published in the Journal of Clinical Oncology

Trial data showed clinical benefit, defined as partial response and stable disease of more than four months following up to eight cycles of treatment, at the maximum tolerated dose in 10 of 13 evaluable patients...Threshold Pharmaceuticals Inc., of South San Francisco, gave an update on its results from a Phase II trial of TH-302 in soft-tissue sarcoma, with additional results from patients who received it as a maintenance therapy after induction with TH-302 and doxorubicin

The HCV program is on track for an investigational new drug application in the first quarter of 2013, and the company expects clinical proof-of-concept data by year-end 2013...Hyperion Therapeutics Inc., of South San Francisco, said results of the Phase II HALT-HE provided new insight into the importance of ammonia in the pathogenesis of hepatic encephalopathy (HE

Genentech Inc., of South San Francisco, a member of the Roche Group, reported results from the ADACTA study, which showed Actemra (tocilizumab) improved signs and symptoms (DAS28 score reduction) of rheumatoid arthritis (RA) significantly more than adalimumab when used alone as a single-agent therapy (without other disease-modifying antirheumatic drugs (DMARD), including methotrexate...The data, compared to month three, showed a further improvement in clinical symptoms linked to RA for patients in

The primary endpoint of the study is clinical benefit of AEZS-108...OxiGene Inc., of South San Francisco, said data from a Phase II trial of Zybrestat (fosbretabulin) in patients with polypoidal choroidal vasculopathy (PCV), which has features similar to age-related macular degeneration (AMD), were presented at the annual meeting of the American Academy of Ophthalmology

Preclinical data reported in September at the Interscience Conference on Antimicrobials and Chemotherapy in San Francisco showed that VIS410 produced 100 percent protection in a mouse prevention model and 100 percent treatment in a mouse treatment model when administered within 48 hours after the onset of symptoms. (See BioWorld Today, Sept. 12, 2012.)

We were losing a lot of patients to these clinical trials...Onyx Pharmaceuticals Inc., of South San Francisco, reported net sales of $18.6 million for newly launched cancer drug Kyprolis (carfilzomib), while sales of Nexavar (sorafenib), as recorded by partner Leverkusen, Germany-based Bayer AG, were $208.2 million, compared with $208.7 million for the same period in 2011

Cellceutix Corp., of Beverly, Mass., said it has recruited the first patients with advanced solid tumors for clinical studies of cancer candidate Kevetrin...Cytokinetics Inc., of South San Francisco, said it opened its Phase IIb BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS) testing tirasemtiv, formerly CK-2017357, in patients with amyotrophic lateral sclerosis (ALS

The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities.

A clinical program is slated to start next year, and GEN-004 "potentially can be taken in directions that cover new diseases," since the bug that causes pneumonia is responsible for other illnesses as well...LoneStar Heart Inc., of San Francisco, completed a milestone-based equity financing worth up to $20 million to support the clinical testing and regulatory clearance of its lead product, Algisyl-LVR, a single-use, self-gelling biopolymer implanted into the heart's left ventricle during surgery

The positive clinical effects of the twice-daily dose of the drug relative to placebo were observed in a variety of standard psoriasis assessment parameters, with the responses accumulating over the 24 weeks...Seattle Genetics Inc., of Bothell, Wash., said it will receive undisclosed milestone payments under its antibody-drug conjugate (ADC) collaboration with South San Francisco-based Genentech Inc., a unit of the Roche Group, triggered by Genentech's advancement of two ADCs into Phase II